1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,804 | 1,036 | 24.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | XSpray Pharma AB: Xspray Pharma provides regulatory status update for Dasynoc and Nilopki | 287 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today provides an update on the regulatory status for its two lead product candidates, Dasynoc and Nilopki. The Company reiterates its plan to resubmit the New Drug Applications... ► Artikel lesen | |
| 20.08. | Xspray's Dasynoc approval bid foiled again by FDA's manufacturer concerns | 3 | FiercePharma | ||
| 19.08. | XSpray Pharma AB: Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc | 1.001 | GlobeNewswire (Europe) | The FDA's Complete Response Letter relates to the previously communicated observations at NerPharMa, concerning outstanding GMP (Good Manufacturing Practice) observations, as well as a request for additional... ► Artikel lesen | |
| 05.08. | XSpray Pharma AB: Xspray Pharma Interim Report Second Quarter 2026 | 518 | GlobeNewswire (Europe) | April-June 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -39,794 thousand (-44,885) Earnings per share before dilution amounted to SEK -0.87 (-1.21) Cash flow... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 26.06. | XSpray Pharma AB: Xspray Pharma provides regulatory update on its US product candidates Nilopki and Dasynoc and notes continued progress with its third-party manufacturer NerPharMa | 652 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) provides an update on the FDA review of its two US new drug applications. For Nilopki®, Xspray has defined an approach to address the items raised... ► Artikel lesen | |
| 05.06. | XSpray Pharma AB: Xspray Pharma Receives CRL from U.S. FDA for Nilopki | 426 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology platform to develop improved versions of marketed protein kinase inhibitors (PKIs)... ► Artikel lesen | |
| 03.06. | XSpray Pharma AB: Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead | 261 | GlobeNewswire (Europe) | Xspray Pharma's two newly implemented long-term incentive programs, LTIP 2025/2028 and LTIP 2026/2029, have reached full participation from the employees to whom they were offered. Participating employees... ► Artikel lesen | |
| 12.05. | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026 | 237 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 12 May 2026.Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 28.04. | XSpray Pharma AB: Interim Report First Quarter 2026 | 353 | GlobeNewswire (Europe) | January-March 2026, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -35,380 thousand (-42,321)Earnings per share before dilution amounted to SEK -0.85 (-1.14)Cash flow... ► Artikel lesen | |
| 23.04. | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue fully utilized | 310 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 14.04. | XSpray Pharma AB: FDA accepts trade name Nilopki for Xspray's drug candidate XS003 (nilotinib) | 855 | GlobeNewswire (Europe) | The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib... ► Artikel lesen | |
| 31.03. | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 248 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 31.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.03.2026 | 431 | Xetra Newsboard | Das Instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY wird ex Kapitalmassnahme gehandelt am 31.03.2026 The instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 26.03. | XSpray Pharma AB: Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased | 301 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 24.03. | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue | 392 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 11.03. | XSpray Pharma AB: Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc - PDUFA date August 25, 2026 | 627 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has accepted Xspray Pharma's resubmitted New Drug Application (NDA) for Dasynoc® for review under the 505(b)(2) procedure. The FDA has set a PDUFA date of... ► Artikel lesen | |
| 26.02. | XSpray Pharma AB: Xspray Pharma re-submits its FDA application for Dasynoc | 409 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc® to the U.S. Food and Drug Administration (FDA). Dasynoc® is the company's lead product candidate - an amorphous... ► Artikel lesen | |
| 26.02. | XSpray Pharma AB: Xspray Pharma appoints Blake Leitch as CEO - Per Andersson continues as Chief Scientific Officer (CSO) | 386 | GlobeNewswire (Europe) | The Board of Directors of Xspray Pharma has today appointed Blake Leitch as CEO of Xspray Pharma, effective no later than June 1, 2026. He brings over 20 years of international experience of marketing... ► Artikel lesen | |
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2025 | 236 | GlobeNewswire (Europe) | October-December 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -37,009 thousand (-82,002)Earnings per share before dilution amounted to SEK -0.89 (-2.36)Cash... ► Artikel lesen | |
| 05.11.25 | XSpray Pharma AB: Interim Report Third Quarter 2025 | 396 | GlobeNewswire (Europe) | July-September 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -47,332 thousand (-82,272)Earnings per share before dilution amounted to SEK -1.25 (-2.44)Cash flow... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,810 | -1,06 % | Starke News und Kaufempfehlung: Vonovia, Evotec und Lahontan Gold Aktie | Starke News von Lahontan Gold. Der Explorer hat eine positive vorläufige Wirtschaftlichkeitsstudie (PEA) für sein Gold-Silber-Projekt Santa Fe im US-Bundesstaat Nevada veröffentlicht. Der Kapitalwert... ► Artikel lesen | |
| BB BIOTECH | 53,00 | -3,11 % | EQS-News: BB BIOTECH AG: BB Biotech Q3 2026: Positive Wertentwicklung, klinische Fortschritte und gezielte Neuinvestitionen | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Quartalsergebnis
BB Biotech Q3 2026: Positive Wertentwicklung, klinische Fortschritte und gezielte Neuinvestitionen
23.10.2026... ► Artikel lesen | |
| MODERNA | 178,42 | -0,19 % | Sell the News: Warum starke Studiendaten den Moderna-Kurs crashen lassen | Die Moderna-Aktie stürzt trotz starker Studiendaten zum Krebsimpfstoff mit Merck um mehr als 25 Prozent ab. Analysten sehen eine klassische Sell-the-News-Reaktion nach monatelanger Kursrallye. Die Moderna-Aktie... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,920 | -0,42 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 19.10.2026 | Folgende Wertpapiere werden in den Handel an der Frankfurter Wertpapierbörse (FWB) aufgenommen.
1. US88025U1097 10X GENOMICS INC
2. NL0000852564 AALBERTS NV
3. SE0016589188 ELECTROLUX AB
4. SE0000115446... ► Artikel lesen | |
| NANOREPRO | 1,685 | +2,74 % | Original-Research: Nanorepro AG (von GBC AG): Kaufen | Original-Research: Nanorepro AG - von GBC AG
21.10.2026 / 14:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
| AAP IMPLANTATE | 1,510 | +3,42 % | aap Implantate: Cornelius Fink und Nicole Kassel neu im Vorstand | Bei aap Implantate kommt es zu Veränderungen im Vorstand. CEO Rubino Di Girolamo wird sein Amt zum 31. Dezember 2026 im Einvernehmen mit dem Aufsichtsrat niederlegen und vorzeitig aus dem Vorstand ausscheiden.... ► Artikel lesen | |
| INFLARX | 1,377 | -1,50 % | Evotec, Valneva oder InflaRx: Welche Biotech-Aktie im Trend-Check vorne liegt - Jetzt lesen! | ||
| TEMPUS AI | 60,66 | +0,46 % | Tempus AI, Inc.: Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC | Study to be presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images
Tempus AI, Inc.... ► Artikel lesen | |
| EDITAS MEDICINE | 2,190 | +2,82 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 50,62 | +1,26 % | BioMarin Pharmaceutical Inc.: BioMarin Appoints Cara Bauer as Chief People Officer | Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries
Appointment Effective Oct. 5, 2026
SAN RAFAEL... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,000 | -0,40 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| EVONEXT | 2,500 | -3,10 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA and Ascend Sport Technology AG sign transaction agreement
12-Oct-2026 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant... ► Artikel lesen | |
| IDORSIA | 4,800 | +0,50 % | Idorsia Pharmaceuticals Ltd: Idorsia presents outstanding results with daridorexant in children and adolescents with insomnia and an expanding body of evidence in adults at Sleep Europe 2026 | Daridorexant, a dual orexin receptor antagonist, is the first investigational treatment in its class to demonstrate positive results in pediatric insomnia disorder, an area in which significant unmet... ► Artikel lesen | |
| MYRIAD GENETICS | 5,172 | 0,00 % | Myriad Genetics presents data on cancer recurrence detection test | ||
| TELIX PHARMACEUTICALS | 8,228 | +1,63 % | Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance | CANBERA (dpa-AFX) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter... ► Artikel lesen |
XSPRAY PHARMA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,898 Euro und damit -0,33 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.